ArticleJournal of pediatrics. Clinical practice2026
Uptake of Respiratory Syncytial Virus Prefusion F Protein Vaccination during Pregnancy and nirsevimab among Infants over Two Seasons in a Single Health System.
Article in Journal of pediatrics. Clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe the uptake of respiratory syncytial virus (RSV) prevention products during the first 2 seasons after availability in the US in a large health system. Study design: Using multisource immunization data from a single health system, we identified a retrospective cohort of infants born from October 2023 to April 2024 (season 1) and from September 2024 to April 2025 (season 2) and their birth parents. We described the uptake of RSV prefusion F protein (RSVpreF) vaccination and nirsevimab and evaluated factors associated with receipt using multivariable logistic regression. Results: Among 10 196 infants, 5868/10 196 (57.6%) were exposed to an RSV-preventive product. Overall, in our maternal-infant dyads, 3850/10 196 (37.8% of total) received RSVpreF, 1837/10 196 infants (18.0% of total) received nirsevimab, and in 181/10 196 (1.8%), both were received. Uptake increased from 2100/4555 (46.1%) in season 1 to 3768/5641 (66.8%) in season 2 ( Conclusions: The uptake of RSV preventive strategies increased across 2 seasons, with a higher uptake of maternal RSVpreF vaccination than nirsevimab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.